We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A group of federal agencies is joining forces with the drug industry to form a public-private partnership to search for new biomarkers in an effort to speed drug development and lower costs.
Dr. Reddy’s Laboratories will begin distributing an authorized generic version of GlaxoSmithKline’s (GSK) migraine drug Imitrex in late 2008, under terms of a patent settlement.
Pfizer is joining the ranks of vaccine manufacturers, with the purchase of a company developing technology that boosts the immune system by shooting microscopic DNA-coated gold particles into the skin.
Gilead Sciences is seeking to beef up its drug pipeline and its emphasis on treatments for pulmonary conditions, announcing Oct. 2 it will acquire Myogen for $2.5 billion.
Barr Pharmaceutical announced Sept. 28 that it is now free to close a deal with Shire, acquiring the rights to Shire’s attention-deficit/hyperactivity disorder drug Adderall immediate-release (IR) tablets.
Par Pharmaceutical will be able to launch a version of Unimed Pharmaceuticals’ testosterone-replacement product AndroGel more than four years before patent expiration under terms of a recent settlement.
The long-running game of escalating bids for control of Croatian generic drugmaker Pliva appears to be over as Actavis has folded its hand and left Barr Pharmaceuticals as the only player at the table.